NASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $3.31 -0.14 (-4.06%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About biote Stock (NASDAQ:BTMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get biote alerts:Sign Up Key Stats Today's Range$3.28▼$3.4050-Day Range$3.07▼$4.9252-Week Range$3.04▼$8.44Volume89,619 shsAverage Volume186,135 shsMarket Capitalization$181.09 millionP/E Ratio12.73Dividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overviewbiote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More… Remove Ads biote Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreBTMD MarketRank™: biote scored higher than 67% of companies evaluated by MarketBeat, and ranked 345th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst Coveragebiote has only been the subject of 1 research reports in the past 90 days.Read more about biote's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-28.00% Earnings GrowthEarnings for biote are expected to decrease by -28.00% in the coming year, from $0.75 to $0.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 12.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.38.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 12.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.63.Read more about biote's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.70% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in biote has recently increased by 13.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.70% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in biote has recently increased by 13.07%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.44 News Sentimentbiote has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for biote this week, compared to 1 article on an average week.Search Interest7 people have searched for BTMD on MarketBeat in the last 30 days. MarketBeat Follows2 people have added biote to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, biote insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,118,936.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.00% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address BTMD Stock News Headlinesbiote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Purchases 13,532 SharesApril 11, 2025 | insidertrades.combiote Corp. (NASDAQ:BTMD) Major Shareholder Buys $23,720.04 in StockApril 8, 2025 | insidertrades.comWhat to do with your collapsing portfolio…There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…April 16, 2025 | Brownstone Research (Ad)biote Corp. (NASDAQ:BTMD) Major Shareholder Acquires $351,920.00 in StockApril 3, 2025 | insidertrades.comInsider Buying: biote Corp. (NASDAQ:BTMD) Director Buys 38,104 Shares of StockMarch 19, 2025 | insidertrades.comGuines Llc Acquires 43,378 Shares of biote Corp. (NASDAQ:BTMD) StockApril 9, 2025 | americanbankingnews.comJefferies Reaffirms Their Buy Rating on biote (BTMD)April 9, 2025 | markets.businessinsider.combiote Corp. (BTMD): Insider Were Buying In Q1 2025April 2, 2025 | msn.comSee More Headlines BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $6.18 on January 1st, 2025. Since then, BTMD shares have decreased by 46.4% and is now trading at $3.31. View the best growth stocks for 2025 here. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) issued its quarterly earnings results on Thursday, August, 10th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.34. The company earned $49.26 million during the quarter, compared to the consensus estimate of $46.76 million. biote had a negative trailing twelve-month return on equity of 32.41% and a net margin of 5.20%. Read the conference call transcript. Who are biote's major shareholders? Top institutional shareholders of biote include Sanders Morris Harris LLC (0.09%). Insiders that own company stock include Guines Llc, Roystone Capital Management Lp, Stephen Mark Cone, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of biote own? Based on aggregate information from My MarketBeat watchlists, some other companies that biote investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings8/10/2023Today4/16/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+141.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio12.73 Forward P/E Ratio4.41 P/E GrowthN/ANet Income$3.32 million Net Margins5.20% Pretax Margin5.99% Return on Equity-32.41% Return on Assets22.26% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.16 Sales & Book Value Annual Sales$197.19 million Price / Sales0.92 Cash Flow$0.34 per share Price / Cash Flow9.60 Book Value($0.58) per share Price / Book-5.71Miscellaneous Outstanding Shares54,710,000Free Float46,784,000Market Cap$181.09 million OptionableNot Optionable Beta1.17 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:BTMD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.